An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Brachyury peptide vaccine (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Paclitaxel (Primary) ; Doxorubicin
Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Sponsors ImmunityBio; NantKwest

10 May 2019 Status changed from not yet recruiting to withdrawn prior to enrolment as trial not initiated.
08 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
05 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jul 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com